Real-world lessons: combining cancer registry and retail pharmacy data for oral cancer drugs
Retail pharmacy data show promise in identifying oral anticancer treatments, enhancing SEER registry efforts, but they require further validation. We propose an evaluation framework, sharing insights and potential use cases for this resource.
Authors
- Lindsey Enewold (ORCID: https://orcid.org/0000-0003-0452-5771)
- Kathleen A. Cronin (ORCID: https://orcid.org/0000-0002-7282-9323)
- Timothy S. McNeel (ORCID: https://orcid.org/0000-0002-7141-5647)
- Jennifer L. Lund (ORCID: https://orcid.org/0000-0002-1108-0689)
- Angela B. Mariotto (ORCID: https://orcid.org/0000-0003-2423-1834)
- Donna R. Rivera (ORCID: https://orcid.org/0000-0002-4565-4556)
- Nadia Howlader (ORCID: https://orcid.org/0000-0002-1989-1478)
- Jennifer L. Stevens (ORCID: https://orcid.org/0009-0000-4602-2959)
Institutions
- University of North Carolina at Chapel Hill (US)
- United States Food and Drug Administration (US)
- Information Management Services (US)
- National Cancer Institute (US)
Publication Details
- Journal
- JNCI Monographs
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1093/jncimonographs/lgae023
- Citations
- 2
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.26
Funders
- National Cancer Institute